Could 2027 be “Europe’s year to shine” when it comes to biopharma investment? That was one of the bold claims made at the opening panel of Fierce Biotech's London Life Sciences Week event on Tuesday.
The panel on the state of biotech funding brought together leading executives from across the spectrum of biopharma investment who sat down with Fierce Biotech Senior Editor James Waldron on stage at the iconic Savoy Hotel in central London.
The event ran a day after life sciences venture capital firm Sofinnova Partners booked its biggest-ever fund worth $815 million, with the cash to be spent on around 15 clinical-stage companies mostly based in Europe.
On stage at Fierce's panel, Antoine Papiernik, chairman and managing partner at Sofinnova, predicted that next year will be “Europe’s time to shine.”
“I think all the ingredients are here,” Papiernik explained. Continuing the food analogy, the investor described China as a “three-star kitchen” for biopharma innovation and the “central feature of the world in our industry.”
China is a place where “people are working with incredible quality and speed, for a quality result,” Papiernik added. But this is also “an amazing opportunity for Europe to actually leverage everything that is being done” in China, he suggested.
Søren Møller, Ph.D., who heads up the seeds investments team of Novo Holdings—the controlling shareholder of Novo Nordisk—told the panel that while “I don’t think we have an innovation problem in Europe,” the region does “have a capital problem.”
While there is money in Europe, it is “just not being deployed in our field,” Sofinnova's Papiernik explained. “In Europe, we call it 'capital risk' not venture capital, so the name is on it—this is risky!”
In response to a question from Fierce's James Waldron, Papiernik said the Nasdaq is not just the biggest game in town for European biotech IPOs, but rather “the only game in town, period.”
“I’m not happy about it, but that’s the reality,” he added.
As a result, while biotechs based outside of the U.S. “must be global ... to compete,” their American peers “don’t have to worry about that.”
European biopharmas “need to be slightly better than the U.S. because of that impediment,” Papiernik concluded.
James Machin, managing director of healthcare investment banking at Morgan Stanley, told the panel that biotechs currently have many different routes to the public markets—namely IPOs, reverse mergers and special purpose acquisition companies—these paths all create the “same outcome.”
Looking ahead to next year, Machin predicted that “we’ll continue to see IPOs as the preferred route” for most biopharmas to go public.
Some welcome good news for Europe's biopharma ecosystem came from Flagship Pioneering yesterday, which announced it had chosen London to set up its first company creation outpost beyond its hometown of Cambridge, Massachusetts. The Flagship Origination Lab, U.K., will “conceive, test, fund and build AI-native platform companies that advance human and planetary health and other frontiers of science and technology,” the company said in its Monday release.
Lena Afeyan, head of U.K. science strategy and innovation at Flagship, described the “strong AI data focus” that is now a central part of the biopharma industry.
“A big part of what brought [Flagship to the U.K.] is AI talent and applying AI talent across all these different fields,” said Afeyan, who predicted “increasing investment in AI companies next year.”